logo
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Yahoo14-05-2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare diseases, empower its employees, and make a meaningful impact on the communities it operates within and serves.
'Since founding Ultragenyx 15 years ago, I've sought to build a next-generation rare disease company that has a meaningful and sustained impact on the entire rare disease community,' said Emil Kakkis, M.D., Ph.D., founder, president, and chief executive officer of Ultragenyx. 'Guided by the principle of doing the right thing, we have engineered our own dynamic approach to drug development while working on broader education and policy initiatives that meaningfully support diagnosis, drug development, regulatory pathways, and clinical care. The sustainability and social impact implications of our actions and decisions are consistently considered and reflected in our 2024 Impact Report.'
The company's approach to corporate responsibility is structured around six key pillars—Innovation, Patients, People, Communities, Planet, and Governance—aligned with its vision to lead the future of rare disease medicine and its mission to transform the lives of people with rare diseases. The 2024 Ultragenyx Impact Report features updates for all six pillars, as well as Sustainability Accounting Standards Board (SASB) and Global Reporting Initiative (GRI) indices. For the full report and more on Ultragenyx's Corporate Responsibility efforts, visit https://www.ultragenyx.com/ultra-committed/corporate-responsibility/.
Highlights from the company's 2024 report include:
Innovation:Ultragenyx is committed to developing and delivering transformative treatments where none exist.
Successfully transferred the manufacturing process of our DTX401 gene therapy to our Gene Therapy Manufacturing Facility (GTMF) in Bedford, Massachusetts
Advanced several key clinical programs to treat rare and ultra-rare diseases, including osteogenesis imperfecta (OI), Angelman syndrome, Sanfilippo syndrome type A (MPS IIIA), and glycogen storage disease type Ia (GSDIa)
Supported more than 80 clinical and non-clinical investigator-sponsored trials (ISTs) globally
Patients:Ultragenyx is committed to supporting the rare disease community through our efforts to develop novel therapies, share our science and expertise, achieve broad access to screening and treatment, and partner with policymakers for meaningful change.
Supported more than 650 patients in 50 countries in gaining access to Ultragenyx treatments through various global expanded access and patient assistance programs since 2013
Successfully advocated for the passage of newborn screening legislation in two more U.S. states
Hosted the ninth and tenth Rare Bootcamp to help patient families, foundations, and organizations seeking to develop novel treatments for rare diseases
People:Ultragenyx is committed to maintaining an inclusive, safe, and healthy environment. The company is also committed to fair and equitable compensation practices that are transparent and free from bias.
Launched the Executive Edge program to support the development of leadership skills at the vice president (VP) and senior VP levels
Maintained a high engagement score of 88% in our employee engagement survey
Communities:Ultragenyx is committed to supporting initiatives that provide meaningful impact for the rare disease community: public health and access to care, Science, Technology, Engineering, Arts, and Mathematics (STEAM) education, and local, at-risk communities.
Approved more than $3 million in charitable donations, independent medical education, and health-related grants across more than 20 countries
Hosted 2nd Annual Ultragenyx Global Days of Service, with employees volunteering in nearly 60 service projects
Planet:Ultragenyx is committed to implementing an environmental strategy that helps minimize its environmental footprint across its business.
Purchased 100% renewable electricity for our corporate headquarters campus in Novato, Calif.
Achieved My Green Lab Green certification at our Translational Sciences lab in Novato, Calif.
Governance:Ultragenyx is committed to strong corporate governance, ethics and integrity, compliance, data protection and security, and responsible procurement.
More than 90% of responders to the annual compliance culture survey stated that the annual compliance training is adequate for them to confidently execute their responsibilities
Maintained a formal Global Human Rights policy to hold ourselves and our vendors to its standards
Ultragenyx Receives External Recognition in 2024Ultragenyx's achievements in 2024 were consistently recognized through several prestigious awards.
In 2024, Ultragenyx was named one of the 100 Most Sustainable Companies by Barron's and one of the Top Places to Work in the USA for the second consecutive year, receiving six Cultural Excellence Awards from Top Workplaces. The company also received accolades from The Boston Globe and the San Francisco Chronicle. Additionally, the company was honored with the MassEcon Gold Award for Economic Impact in the Northeast region, celebrating its significant contributions to the Massachusetts economy, and was recognized as one of the Best Places for Working Parents in Massachusetts.
About UltragenyxUltragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Forward-Looking Statements and Use of Digital Media
This press release and the 2024 Ultragenyx Impact Report and other materials cross-referenced in this press release contain statements that are aspirational or reflective of our views about the company's future performance that constitute 'forward looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified through the inclusion of words such as 'aim,' 'anticipate,' 'aspire,' 'believe,' commit,' 'endeavor,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'plan,' 'seek,' 'strive,' 'target,' 'will,' vision,' 'mission,' 'strategy,' 'commitment' and 'work,' or similar statements or variations of such terms and other similar expressions. The forward-looking statements in this document and the materials cross-referenced concern Ultragenyx's goals, progress or expectations with respect to corporate responsibility, sustainability, patients, products, product candidates, employees, environmental matters, policy and business risks and opportunities. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in such statements. These statements are based on numerous assumptions that the company believes are reasonable but are open to a wide range of uncertainties and business risks. In addition, these statements may be based on standards for measuring progress that are still developing, controls and processes that continue to evolve, and assumptions that are subject to change in the future, and certifications, representations or data reviewed or provided by third parties Consequently, actual results may vary materially from what is contained in a forward-looking statement.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, and its subsequent periodic reports filed with the SEC. Forward-looking statements are aspirational and are not guarantees or promises that goals or targets will be met. Ultragenyx undertakes no obligation to update any forward-looking or other statements, whether as a result of new information, future events, or otherwise, and notwithstanding any historical practice of doing so. Ultragenyx may determine to adjust any goals and targets or establish new ones to reflect changes in its business. The information included in, and any issues identified as material for purposes of, the 2024 Ultragenyx Impact Report is not an indication that they are considered material to Ultragenyx, its investors or other stakeholders, or required to be disclosed in the company's filings, in each case under SEC reporting or any other laws or requirements that may apply to the company. In the context of this report, the term 'material' is distinct from, and should not be confused with, such term as defined for SEC or other mandatory reporting purposes.
In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx's Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).
Ultragenyx Contacts Investors Joshua Higa(415) 475-6370ir@ultragenyx.com
MediaJoey Fleurymedia@ultragenyx.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem
North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem

Yahoo

time21 minutes ago

  • Yahoo

North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem

The Minimal Residue Disease (MRD) Testing Market is projected to reach USD 4.50 billion by 2030, with a CAGR of 10.1% from 2025. Key drivers include the rising use of MRD tests in cancer prognosis and personalized medicine. In 2024, flow cytometry and hematological malignancies held major market shares. North America leads due to advanced diagnostics and healthcare infrastructure. This report offers comprehensive insights and strategic recommendations. Minimal Residual Disease Testing Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), By Cancer Type (Hematological Malignancy, Solid Tumors), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030" report has been added to global minimal residual disease testing market size is estimated to reach USD 4.50 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime. MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective Residue Disease Testing Market Report Highlights By technology, the flow cytometry segment held a dominant share in the minimal residual disease testing market in 2024, owing to the high sensitivity and wide applicability of MRD testing. By cancer type, the hematological malignancy cancer dominated the market with a revenue share of 68.58% in 2024, owing to the increasing prevalence of hematological malignancy. By end-use, the hospitals and specialty clinics segment is the highest revenue-generating segment in 2024, owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics. North America dominated the minimal residual disease testing market in 2024, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape. Key Attributes: Report Attribute Details No. of Pages 320 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.5 Billion Forecasted Market Value (USD) by 2030 $4.5 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Companies Featured Exact Sciences Corporation GRAIL, LLC Veracyte, Inc. Natera, Inc. Guardant Health F. Hoffmann-La Roche Ltd FOUNDATION MEDICINE, INC. QIAGEN mdxhealth Bio-Techne For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Minimal Residual Disease Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

European Firms Embrace Google Cloud Ecosystem
European Firms Embrace Google Cloud Ecosystem

Business Wire

time22 minutes ago

  • Business Wire

European Firms Embrace Google Cloud Ecosystem

LONDON--(BUSINESS WIRE)--European enterprises are rapidly advancing cloud strategies, often using AI tools and services from the expanding Google Cloud ecosystem, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. European enterprises are adopting agentic AI technologies to extend their capacity to meet the demands of increasingly complex processes. This strategy positions them for enhanced growth opportunities and innovation. Share The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Europe finds that AI capabilities are helping enterprises use the cloud to enhance operational efficiency and strategic decision-making. For many companies, the AI-powered tools and services in Google Cloud's broad technology suite, especially agentic AI offerings, play a major role in these efforts. 'European enterprises are adopting agentic AI technologies to extend their capacity to meet the demands of increasingly complex processes,' said Dorotea Baljević, director and EMEA industrial AI lead at ISG. 'This strategy positions them for enhanced growth opportunities and innovation.' The focus on using agentic AI to optimize key software development tasks, including code generation and testing, is increasing among European enterprises, the report says. Businesses are leveraging agentic AI for efficient inventory management and personalized product recommendations, driving overall business growth and operational excellence across various industries. There is a growing emphasis on responsible AI in Europe to reduce bias and enhance data security, ISG says. Google Cloud ecosystem providers are supporting these efforts by strengthening AI practices and cybersecurity measures, enabling businesses to confidently navigate the decision-making functions of AI systems while protecting sensitive information across organizational boundaries. This focus ensures ethical AI integration and protects enterprise data against emerging security threats. European enterprises are also adopting data modernization strategies to ensure high-quality, accessible data, which is crucial for agentic AI success, the report says. By migrating legacy data to cloud platforms, businesses gain access to tools that can improve insights and decision-making. Google Cloud ecosystem providers offer expertise in integrating advanced data management, analytics and AI into unified platforms, allowing enterprises to streamline operations and enhance business intelligence. Demand for cloud sovereignty solutions is surging in Europe as enterprises seek to comply with stringent privacy regulations and maintain control over their data systems, ISG says. Enterprises are implementing isolated servers in cloud data centers to address geopolitical uncertainties. Google Cloud ecosystem providers support these efforts by delivering services that ensure independent management of cloud environments, which enhances data security. 'Enterprises are adopting AI and data strategies to enhance productivity while ensuring security and compliance,' said Mark Purdy, principal analyst, ISG Provider Lens Research, and the lead author of the report. 'These initiatives foster growth and operational resilience.' The report also explores other European cloud trends, including the growing adoption of hybrid and multicloud architectures for enhanced flexibility and security and an increasing focus on FinOps for cloud cost optimization and strategic financial management. For more insights into the cloud challenges faced by European enterprises, along with ISG's advice for addressing them, see the ISG Provider Lens ® Focal Points briefing here. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Europe evaluates the capabilities of 37 providers across four quadrants: Google Cloud Professional Services (Consulting and Migration), Google Cloud Managed Services, Google Cloud Enterprise Data Infrastructure Services and Google Cloud GenAI and AI Services. The report names Accenture, HCLTech, TCS and Wipro as Leaders in all four quadrants. Cognizant, GFT and NTT DATA are named as Leaders in three quadrants each. Atos, LTIMindtree, Quantiphi and T-Systems are named as Leaders in two quadrants each, and DXC Technology, PCG and Telana are named as Leaders in one quadrant each. In addition, Telana is named as a Rising Star — a company with a 'promising portfolio' and 'high future potential' by ISG's definition — in two quadrants. SFEIR is named as a Rising Star in one quadrant. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among Google Cloud ecosystem providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. Customized versions of the report are available from Telana. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Europe is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens ® Research The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

Pony.ai Kicks Off 24/7 Robotaxi Operation in Major Chinese Cities
Pony.ai Kicks Off 24/7 Robotaxi Operation in Major Chinese Cities

Yahoo

timean hour ago

  • Yahoo

Pony.ai Kicks Off 24/7 Robotaxi Operation in Major Chinese Cities

GUANGZHOU, China, July 25, 2025 /PRNewswire/ -- (NASDAQ: PONY), a global leader in autonomous driving technology, today starts around-the-clock Robotaxi operation in the Chinese megacities of Guangzhou and Shenzhen, two of southern China's dynamic economic engines. This move marks a major step forward in the company's China development, expanding its Robotaxi operation window from 15 hours a day to full 24/7 availability. In the meantime, also extended its Robotaxi testing window in the Chinese capital city of Beijing to 24 hours daily. The initiative builds on extensive operational foundation, with over 50 million kilometers of global autonomous testing. These efforts cover a wide range of traffic and lighting conditions — from midday congestion to late-night driving — providing robust validation of system performance under real-world scenarios. The company's proprietary autonomous driving system — its "virtual driver" — has logged more than 500,000 hours of driverless operation. According to internal metrics, the system has achieved a safety record up to ten times safer than that of human drivers. This continuous validation has sharpened the system's ability to respond to complex road environments and changing weather conditions. At the heart of sensing and perception capabilities is a multi-sensor fusion architecture that integrates high-performance 128-beam LiDAR, 8-megapixel cameras, and 4D imaging millimeter-wave radar. Together, these components deliver real-time, 360-degree perception — even in low-light or nighttime settings. Unlike vision-only systems that rely heavily on ambient light, use of active sensing technologies such as LiDAR and radar adds critical redundancy. This enables the detection of low-contrast objects like pedestrians in dark clothing, reduces the impact of headlight glare, and supports safe navigation on poorly lit or unlit roads. This level of capability is made possible by the company's advanced autonomous driving software stack, built on its "PonyWorld foundation model and virtual driver" architecture. Deployed in its seventh-generation Robotaxi fleet, the system enables stable, high-precision detection of road features, signage, vehicles, and pedestrians — from nearby blind spots to distances of up to 650 meters. To ensure reliability in harsh conditions, the vehicles are also equipped with a proprietary sensor self-cleaning system that mitigates the impact of rain, fog, dusts and road debris. As continues to scale its seventh-generation Robotaxi fleet across Beijing, Shanghai, Guangzhou, and Shenzhen, the company is positioning its always-on trials to help reshape urban transportation. The 24/7 operation initiative underscores commitment to accelerating the commercial viability of Robotaxi services — improving late-night mobility while setting new standards in safety and availability. As cities grow quieter after dark, late-night commuters may find a new kind of travel companion: a safe, reliable Robotaxi — always on, always ready. View original content: SOURCE Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store